Pfizer’s combination of morphine and naltrexone (Embeda) will be the third opioid painkiller to win the FDA’s abuse-deterrent label. The FDA said data have shown that the combination should reduce abuse when the drug is crushed and then eaten or snorted. When the tablet is crushed, the naltrexone — an opioid antagonist — blocks the euphoric effects of morphine. One study also showed that Embeda may reduce drug “likability” among those who abuse it via the intravenous route, but FDA said further study is needed. The agency also noted that Embeda can still be abused or misused when swallowed whole, and it is requiring postmarketing studies to further assess its abuse-deterrent features.
Read the full overview from MedPage Today here.
Read Louisiana Comp Blog’s take on emergent medical issues in our state, including pain management, here.